

**Questions for Advisory Committee Members  
Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and  
Risk Management Advisory Committee Meeting  
July 30, 2007**

1. Please comment on the contribution of the meta-analysis of the 42 controlled clinical trials (e.g., strengths and limitations) to the understanding of cardiac ischemic risk for Avandia.
2. Please comment on the contribution of the observational cohort studies (e.g., strengths and limitations) to the understanding of cardiac ischemic risk for Avandia.
3. Please comment on the contribution of large randomized controlled trials of rosiglitazone (e.g., strengths and limitations of DREAM, ADOPT, and RECORD) to the understanding of cardiac ischemic risk for Avandia.
4. Do the available data support a conclusion that Avandia increases cardiac ischemic risk in type 2 diabetes mellitus (**VOTE requested**)?
  - If yes, is there evidence that this risk is greater than other available therapies for the treatment of type 2 diabetes mellitus?
5. Does the overall risk-benefit profile of Avandia support its continued marketing in the US (**VOTE requested**)?
  - If yes, please comment on what FDA should do to maximize the risk-benefit considerations (e.g., limit to certain patients, incorporate a boxed warning....)